Background: percutaneous biopsies are low-cost, safe procedures with key role in diagnosis of lung cancer. With the need for more tissue for extensive testing panels, are core biopsies (CB) superior to fine needle aspiration(FNA)?Methods: Patients having US-guided biopsies for suspected thoracic...
Primary lung cancer is one of the most common malignant tumors in China. Approximately 60% of lung cancer patients have distant metastasis at the initial diagnosis, so it is necessary to find new tumor markers for early diagnosis and individualized treatment. Tumor markers contribute to the early...
MicroRNAs, among the most extensively studied ncRNAs in oncology research, can be identified through various liquid biopsy techniques that detect miRNAs released by CTCs and tumor cells [51]. Detecting miRNAs is of paramount importance as biomarkers for the diagnostic assessment of lung cancer. For i...
Accurate prediction of chemo- or targeted therapy responses for patients with similar driver oncogenes through a simple and least-invasive assay represents an unmet need in the clinical diagnosis of non-small cell lung cancer. Using a single-cell on-chip metabolic cytometry and fluorescent metabolic ...
Currently, immunotherapy for lung cancer mostly refers to the application of immune checkpoint inhibitors. Immune checkpoints are a large group of molecules expressed in immune cells, antigen-presenting cells, tumor cells, etc. and play a role in inhibiting or activating the acquired immune system,...
CT-guided biopsies require patients to be able to hold still on the CT table for up to 30 minutes. A very small nick is made in the skin at the site where the biopsy needle is to be inserted. Under CT guidance, the radiologist will insert the needle at the site already marked and ...
CTゞuided transthoracic needle biopsy for evaluation of PD㎜1 expression: Comparison of 22C3 and SP263 assaysImage‐guided biopsyimmunohistochemistrynon‐small cell lung cancerPD‐L1 proteinBackgroundAlthough there have been several studies on concordance of different assays testing programmed cell death ...
Increase cancer treatment success rates with LBL’s revolutionary liquid biopsy for cancer screening and diagnosis.
Small-cell lung cancer (SCLC) transformation has been described as another resistance mechanism, accounting for 3 to 10% of all the EGFR-TKI-resistant cases [98]. However, this might be underestimated, due to the absence of re-biopsy at the time of progression. The most common mutations ass...
Since the publication of the first International Association for the Study of Lung Cancer (IASLC) liquid biopsy statement in 2018, several additional advances have been made in this field, leading to changes in the therapeutic decision-making algorithm for advanced NSCLC and prompting this 2021 ...